Metastatic disease accounts for the majority of cancer-related mortalities. The genes and proteins involved in metastasis have long been sought after as potential therapeutic targets. Our tumor portfolio contains a number of proprietary, efficient, and reproducible metastasis models.

MRI, CT, PET, and optical imaging technologies provide rapid, non-invasive, highly efficient, and accurate determination of drug response in these models. In particular, bioluminescence imaging, through the use of luciferase-enabled tumor lines, is a highly efficient method for tracking metastatic disease. The metastasis models we use are evaluated for reproducible growth characteristics in vivo and are available for both preventative and staged-treatment testing.

In order to establish metastasis models, varying types of transmission modes include:

  • Spontaneous metastasis from implanted solid tumors
  • Intracardiac cell injection
  • Intravenous cell injection
  • Intrasplenic cell injection
  • Peritibial implantation

We continually develop and optimize new metastasis models.